TY - JOUR
T1 - Role of imaging in low-grade cutaneous B-cell lymphoma presenting in the skin
AU - Kheterpal, Meenal K.
AU - Dai, Julia
AU - Geller, Shamir
AU - Pulitzer, Melissa
AU - Ni, Andy
AU - Myskowski, Patricia L.
AU - Moskowitz, Alison
AU - Kim, Jinah
AU - Hong, Eric K.
AU - Fong, Sophia
AU - Hoppe, Richard T.
AU - Kim, Youn H.
AU - Horwitz, Steven M.
N1 - Funding Information:
Funding sources: Supported in part by the National Institutes of Health, National Cancer Institute Cancer Center Support Grant P30 CA008748.
Publisher Copyright:
© 2019 American Academy of Dermatology, Inc.
PY - 2019/10
Y1 - 2019/10
N2 - Background: Whole-body imaging is the current standard of care for staging all patients presenting with skin lesions of B-cell lymphomas (BCLs), regardless of skin disease extent; however, supporting data are lacking. Objective: To determine the clinical utility of imaging in the detection of systemic involvement in low-grade cutaneous BCLs in the skin. Methods: Retrospective cohort analysis of patients presenting with cutaneous lesions of BCLs at Memorial Sloan Kettering Cancer Center and Stanford University during 1997-2016. Results: At initial staging, of the 522 patients, extracutaneous disease was noted in 3.6% and 8.8% of patients with marginal zone lymphoma (MZL, n = 306) and follicle center lymphoma (FCL, n = 216) histology, respectively. In patients with systemic involvement, imaging alone identified 81.8% (9/11) of MZL cases and 89.4% of follicular lymphoma cases. In primary cutaneous MZL, 1.7% of patients subsequently had extracutaneous involvement (median follow-up 45 months), and in primary cutaneous FCL. 3.0% subsequently had extracutaneous involvement (median follow-up 47 months). Limitations: This was a retrospective study. Conclusion: Imaging is effective at identifying patients with systemic involvement in indolent BCLs present in the skin; however, incidence is low. After negative initial staging, primary cutaneous MZL patients may be followed clinically without routine imaging.
AB - Background: Whole-body imaging is the current standard of care for staging all patients presenting with skin lesions of B-cell lymphomas (BCLs), regardless of skin disease extent; however, supporting data are lacking. Objective: To determine the clinical utility of imaging in the detection of systemic involvement in low-grade cutaneous BCLs in the skin. Methods: Retrospective cohort analysis of patients presenting with cutaneous lesions of BCLs at Memorial Sloan Kettering Cancer Center and Stanford University during 1997-2016. Results: At initial staging, of the 522 patients, extracutaneous disease was noted in 3.6% and 8.8% of patients with marginal zone lymphoma (MZL, n = 306) and follicle center lymphoma (FCL, n = 216) histology, respectively. In patients with systemic involvement, imaging alone identified 81.8% (9/11) of MZL cases and 89.4% of follicular lymphoma cases. In primary cutaneous MZL, 1.7% of patients subsequently had extracutaneous involvement (median follow-up 45 months), and in primary cutaneous FCL. 3.0% subsequently had extracutaneous involvement (median follow-up 47 months). Limitations: This was a retrospective study. Conclusion: Imaging is effective at identifying patients with systemic involvement in indolent BCLs present in the skin; however, incidence is low. After negative initial staging, primary cutaneous MZL patients may be followed clinically without routine imaging.
KW - imaging
KW - primary cutaneous B-cell lymphoma
KW - prognosis
KW - systemic involvement of cutaneous B-cell lymphoma
UR - http://www.scopus.com/inward/record.url?scp=85070812125&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070812125&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2019.01.037
DO - 10.1016/j.jaad.2019.01.037
M3 - Article
C2 - 30703460
AN - SCOPUS:85070812125
SN - 0190-9622
VL - 81
SP - 970
EP - 976
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 4
ER -